The first-in-human implantation of the Tiara transcatheter mitral valve was successfully performed in January at St. Paul’s Hospital in Vancouver, according to a press release issued by Neovasc Inc.
The patient was a 73-year-old man with severe functional mitral regurgitation who was considered a high-risk candidate for conventional valve repair or replacement surgery.
The transapical procedure was associated with elimination of mitral regurgitation and significantly improved heart function, without the need for cardiac bypass support or the incidence of significant paravalvular leak and procedural complications, according to the release.
“We are very pleased that this first implantation went so smoothly and that the patient’s outcome to date is so positive,” Anson Cheung, MD, professor of surgery and director of cardiac transplant at St. Paul’s Hospital, stated in the release. “His recovery has been uneventful and we will continue to follow him closely over the coming months.” The implantation was performed by Cheung and John G. Webb, MD, director of interventional cardiology at St. Paul’s Hospital.
Tiara is a self-expanding bioprosthesis that replaces a native mitral valve without the need for CABG or cardiac bypass support.
“The ability to implant a prosthetic mitral heart valve using a transcatheter, minimally-invasive approach instead of conventional open-chest, open-heart surgery would provide a much-needed alternative for the many patients who are considered at high risk for conventional surgery,” Cheung stated in the release.